M. Guérin

TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors

A. Trautmann, G. Altan-Bonnet, N. Bercovici, 2018, bioRxiv.

Dynamic CD8+ T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy

N. Bercovici, E. Peranzoni, M. Guerin, 2022, Cancers.

Type I interferons (IFN) are being rediscovered as potent anti-tumoral agents. Activation of the STimulator of INterferon Genes (STING) by DMXAA can induce a strong production of IFN and the rejection

A. Trautmann, G. Altan-Bonnet, N. Bercovici, 2019 .

The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer

A. Trautmann, N. Bercovici, E. Donnadieu, 2019, Front. Immunol..

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

N. Bercovici, M. Alifano, D. Damotte, 2018, Proceedings of the National Academy of Sciences.

Preclinical murine tumor models: A structural and functional perspective

A. Trautmann, N. Bercovici, B. J. Van den Eynde, 2020, eLife.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression

A. Trautmann, N. Bercovici, E. Peranzoni, 2017, Oncoimmunology.